ACLX

Company Overview — What Does Arcellx, Inc. Do?

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland. Arcellx, Inc. (ACLX) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Rami Elghandour and employs approximately 80 people. With a market capitalization of $6.7B, ACLX is one of the notable companies in the Healthcare sector.

Arcellx, Inc. (ACLX) Stock Rating — Reduce (April 2026)

As of April 2026, Arcellx, Inc. receives a Reduce rating with a composite score of 39.5/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ACLX ranks #1,999 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Arcellx, Inc. ranks #215 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ACLX Stock Price and 52-Week Range

Arcellx, Inc. (ACLX) currently trades at $114.83. The stock gained $0.03 (0.0%) in the most recent trading session. The 52-week high for ACLX is $114.80, which means the stock is currently trading 0.0% from its annual peak. The 52-week low is $47.86, putting the stock 139.9% above its annual trough. Recent trading volume was 790K shares, suggesting relatively thin trading activity.

Is ACLX Overvalued or Undervalued? — Valuation Analysis

Arcellx, Inc. (ACLX) carries a value factor score of 29/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 16.69x, versus the sector average of 2.75x. The price-to-sales ratio is 143.87x, compared to 1.66x for the average Healthcare stock.

At current multiples, Arcellx, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Arcellx, Inc. Profitability — ROE, Margins, and Quality Score

Arcellx, Inc. (ACLX) earns a quality factor score of 22/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -48.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -32.6% versus the sector average of -33.1%.

On a margin basis, Arcellx, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -750.6% (sector: -66.1%). Net profit margin stands at -672.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -81.9% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ACLX Debt, Balance Sheet, and Financial Health

Arcellx, Inc. has a debt-to-equity ratio of 50.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.44x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $79M.

ACLX has a beta of 0.84, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Arcellx, Inc. is 54/100, reflecting average volatility within the normal range for its sector.

Arcellx, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Arcellx, Inc. reported revenue of $47M and earnings per share (EPS) of $-4.07. Net income for the quarter was $-197M. Gross margin was 100.0%. Operating income came in at $-223M.

In FY 2025, Arcellx, Inc. reported revenue of $22M and earnings per share (EPS) of $-4.07. Net income for the quarter was $-229M. Revenue grew -79.4% year-over-year compared to FY 2024. Operating income came in at $-253M.

In Q3 2025, Arcellx, Inc. reported revenue of $5M and earnings per share (EPS) of $-0.99. Net income for the quarter was $-56M. Revenue grew -81.0% year-over-year compared to Q3 2024. Operating income came in at $-62M.

In Q2 2025, Arcellx, Inc. reported revenue of $8M and earnings per share (EPS) of $-0.94. Net income for the quarter was $-53M. Revenue grew -72.4% year-over-year compared to Q2 2024. Operating income came in at $-59M.

Over the past 8 quarters, Arcellx, Inc. has demonstrated a growth trajectory, with revenue expanding from $27M to $47M. Investors analyzing ACLX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ACLX Dividend Yield and Income Analysis

Arcellx, Inc. (ACLX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ACLX Momentum and Technical Analysis Profile

Arcellx, Inc. (ACLX) has a momentum factor score of 69/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 19/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ACLX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Arcellx, Inc. (ACLX) ranks #215 out of 838 stocks based on the Blank Capital composite score. This places ACLX in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ACLX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ACLX vs S&P 500 (SPY) comparison to assess how Arcellx, Inc. stacks up against the broader market across all factor dimensions.

ACLX Next Earnings Date

No upcoming earnings date has been announced for Arcellx, Inc. (ACLX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ACLX? — Investment Thesis Summary

The quantitative profile for Arcellx, Inc. suggests caution. The quality score of 22/100 flags below-average profitability. The value score of 29/100 indicates premium valuation. Price momentum is positive at 69/100, suggesting the trend favors buyers.

In summary, Arcellx, Inc. (ACLX) earns a Reduce rating with a composite score of 39.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ACLX stock.

Related Resources for ACLX Investors

Explore more research and tools: ACLX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ACLX head-to-head with peers: ACLX vs AZN, ACLX vs SLGL, ACLX vs VMD.